The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The chemotherapy-induced nausea and vomiting (CINV) market have exhibited robust growth, reaching $2.69 billion in 2023, with a projected increase to $2.92 billion in 2024, marking a significant compound annual growth rate (CAGR) of 8.4%. The surge in the historic period is attributed to the increased use of chemotherapy, advancements in antiemetic agents, adherence to clinical guidelines, and the active role of patient advocacy.

Rising Cancer Prevalence Spurs Growth

1.1 The Cancer Epidemic and CINV Market
The escalating prevalence of cancer globally is a primary driver propelling the growth of the CINV market. With cancer cases projected to reach 1.9 million in the United States alone in 2023, the urgency to develop effective anti-emetic treatments to address CINV becomes paramount. The distressing side effects of chemotherapy necessitate a focus on targeted therapies and advancements in understanding the underlying mechanisms of CINV.

1.2 Industry Leaders Addressing the Challenge
Major players in the CINV market, including Pfizer Inc., Roche Holding AG, and AstraZeneca PLC, are pivotal in developing innovative solutions to counteract the rising prevalence of cancer. Their commitment to advancing anti-emetic treatments showcases the industry’s dedication to enhancing the quality of life for cancer patients undergoing chemotherapy.

View More On The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report 2023 – https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Pioneering Transdermal Delivery System (TDS) Innovations

2.1 TDS Revolutionizing CINV Treatment
In the pursuit of innovation, major companies in the CINV market are revolutionizing treatment through transdermal delivery systems (TDS). Starton Therapeutics Inc.’s STAR-OLZ transdermal delivery system (TDS) is a noteworthy example, receiving FDA approval in April 2021. This multi-day olanzapine TDS addresses CINV throughout the duration of a five-day therapy, showcasing the potential of TDS in providing controlled and effective antiemetic treatment.

2.2 Cumberland Pharmaceuticals’ Strategic Acquisition
In January 2022, Cumberland Pharmaceuticals Inc. expanded its CINV portfolio by acquiring SANCUSO from Kyowa Kirin Inc. for $13.5 million. This strategic move enables Cumberland to take full commercial responsibility for the chemotherapy-induced nausea and vomiting (CINV) drug, strengthening its position in the market and ensuring comprehensive control over marketing, promotion, distribution, manufacturing, and medical support operations.

Segmentation and Regional Outlook

3.1 Market Segmentation
The chemotherapy-induced nausea and vomiting (CINV) market is segmented based on form, drug class, emetogenic risk, distribution channel, and application. Key segments include injectables, oral medications, and transdermal patches. Drug classes encompass 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids, and other drug classes. Emetogenic risk categorizes chemotherapy into highly emetogenic, moderately emetogenic, and low emetogenic. Distribution channels include CINV hospitals, cancer research institutes, retail pharmacies, online pharmacies, and drug stores. Applications span gynecology, urology, gastrointestinal surgery, and other medical fields.

3.2 Regional Dynamics
As of 2023, North America takes the lead in the chemotherapy-induced nausea and vomiting (CINV) market. Looking ahead, the Asia-Pacific region is anticipated to be a key player, reflecting the global nature of the market and the increasing focus on cancer treatment and care worldwide. 

Request A Sample Of The Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=13031&type=smp

The Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2023  provides a comprehensive overview on the chemotherapy-induced nausea and vomiting (CINV) market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the chemotherapy-induced nausea and vomiting (CINV) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Chemotherapy-Induced Anemia Global Market Report 2023
Cancer Biologics Global Market Report 2023
Viral Vectors And Plasmid DNA Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model